243 related articles for article (PubMed ID: 29551430)
1. Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis.
Gallagher JS; Missmer SA; Hornstein MD; Laufer MR; Gordon CM; DiVasta AD
J Pediatr Adolesc Gynecol; 2018 Aug; 31(4):376-381. PubMed ID: 29551430
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
Sadler Gallagher J; Feldman HA; Stokes NA; Laufer MR; Hornstein MD; Gordon CM; DiVasta AD
J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):215-222. PubMed ID: 26927501
[TBL] [Abstract][Full Text] [Related]
3. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
[TBL] [Abstract][Full Text] [Related]
4. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
Hornstein MD; Surrey ES; Weisberg GW; Casino LA
Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
[TBL] [Abstract][Full Text] [Related]
5. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
Chwalisz K; Surrey E; Stanczyk FZ
Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
Soliman AM; Bonafede M; Farr AM; Castelli-Haley J; Winkel C
J Manag Care Spec Pharm; 2016 May; 22(5):573-87. PubMed ID: 27123918
[TBL] [Abstract][Full Text] [Related]
7. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.
Surrey ES; Judd HL
J Clin Endocrinol Metab; 1992 Aug; 75(2):558-63. PubMed ID: 1386374
[TBL] [Abstract][Full Text] [Related]
8. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
Surrey ES; Hornstein MD
Obstet Gynecol; 2002 May; 99(5 Pt 1):709-19. PubMed ID: 11978277
[TBL] [Abstract][Full Text] [Related]
9. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
Surrey ES; Voigt B; Fournet N; Judd HL
Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
[TBL] [Abstract][Full Text] [Related]
10. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group.
Surrey ES
Fertil Steril; 1999 Mar; 71(3):420-4. PubMed ID: 10065775
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey ES
Curr Opin Obstet Gynecol; 2010 Aug; 22(4):283-8. PubMed ID: 20498596
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Adolescent Endometriosis Before, During, and After Use of Gonadotropin-Releasing Hormone Agonists: A Retrospective Cohort Study.
Shim JY; Laufer MR; DiVasta AD
J Pediatr Adolesc Gynecol; 2023 Oct; 36(5):472-475. PubMed ID: 37178784
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis.
Kim NY; Ryoo U; Lee DY; Kim MJ; Yoon BK; Choi D
Eur J Obstet Gynecol Reprod Biol; 2011 Jan; 154(1):85-9. PubMed ID: 20832162
[TBL] [Abstract][Full Text] [Related]
14. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.
Divasta AD; Laufer MR; Gordon CM
J Pediatr Adolesc Gynecol; 2007 Oct; 20(5):293-7. PubMed ID: 17868896
[TBL] [Abstract][Full Text] [Related]
15. [GnRH agonist and add back therapy--indications, results and problems in the treatment of genital endometriosis].
Mettler L
Zentralbl Gynakol; 2003; 125(7-8):267-75. PubMed ID: 14505262
[TBL] [Abstract][Full Text] [Related]
16. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
[TBL] [Abstract][Full Text] [Related]
17. Add-back therapy: extending safety and efficacy of GnRH analogues in the gynecologic patient.
Surrey ES
Gynecol Obstet Invest; 1998; 45 Suppl 1():31-4; discussion 35. PubMed ID: 9628522
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain.
Friedman AJ; Hornstein MD
Fertil Steril; 1993 Aug; 60(2):236-41. PubMed ID: 8339817
[TBL] [Abstract][Full Text] [Related]
19. The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis.
DiVasta AD; Laufer MR
Curr Opin Obstet Gynecol; 2013 Aug; 25(4):287-92. PubMed ID: 23770813
[TBL] [Abstract][Full Text] [Related]
20. Low-dose add-back therapy during postoperative GnRH agonist treatment.
Tsai HW; Wang PH; Huang BS; Twu NF; Yen MS; Chen YJ
Taiwan J Obstet Gynecol; 2016 Feb; 55(1):55-9. PubMed ID: 26927249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
